Recently, Acchrom-Tech announced that it has completed a Series A financing of 100 million yuan, which is the second financing of 100 million yuan completed by Acchrom-Tech in the past year. This round of financing is led by Honghui Fund, followed by Dinghui Investment, and old shareholders Boyuan Capital and Chende Capital invest in excess proportion. The financing is mainly used to expand chromatography sales channels and improve service systems. Changhai Capital continues to serve as the exclusive financial advisor for the company's financing.

Acchrom-Tech: Seize the historical opportunity, forge ahead with determination, maintain a rational mind, and diligently practice internal skills

Liquid chromatographs and their consumables are very important components in the analytical instrument industry, with a wide range of applications in pharmaceuticals, food, environmental protection, petrochemicals, and life sciences. The domestic market capacity reaches 10 billion yuan annually and still maintains a high growth rate; More than 90% of the liquid chromatograph market is currently monopolized by imported products, and there is huge substitution space for domestic brands. With supply chain security and the upstream of the industrial chain being valued by countries and investment institutions, many analytical instrument enterprises, including chromatography, have become "small flames" in the "capital cold winter".

In response to this situation, Acchrom-Tech has comprehensively and rationally formulated the company's development plan and strategy. We must seize the opportunity of the times and actively strive for business opportunities; We must always maintain a low-key and pragmatic attitude, improve our sales and service capabilities, and achieve greater business breakthroughs.

Complete the full closed-loop of the product and provide world-class standard product solutions

Compared to other domestic manufacturers, Acchrom-Tech has advantages in the following aspects: (1) fully independent chromatographic instruments, consumables, and software system; (2) A few domestic enterprises that have achieved mass production of liquid chromatographs and sold them to mid to high end mainstream customers.

In terms of equipment and consumables, Acchrom-Tech has launched 5 independent models of high-efficiency and ultra-high performance liquid chromatography and liquid chromatography-mass spectrometry, as well as nearly 100 categories of liquid chromatography columns and pre-treatment consumables, fully meeting the research and production needs of customers in the fields of pharmaceuticals, food, environmental protection, petrochemicals, and life sciences. The company's entire machine has undergone long-term evaluation by multiple well-known enterprises and institutions, and its product performance and stability can benchmark against imported products.

The efficiency, reliability, and compliance of chromatographic analysis results largely depend on software. Regulatory authorities at home and abroad have extremely high requirements for chromatographic software. Without high-performance compliant chromatographic software, domestic chromatographic manufacturers find it difficult to penetrate mainstream pharmaceutical enterprise customers. In October 2022, Acchrom-Tech released its first domestically produced highly compliant chromatographic control software. The software was independently developed by Acchrom-Tech and has completely independent intellectual property rights. It has full chain auditing and advanced intelligent data analysis capabilities. At present, multiple regulatory agencies and users have completed the evaluation of this compliant software, and the product fully meets domestic and foreign regulatory requirements. Compared with existing software on the market, the design concept is more advanced, the operation is more convenient, and the functions are more diverse. In the future, the software is also planned to be expanded in analytical instruments such as liquid chromatography-mass spectrometry and gas chromatograph.

Polishing application capabilities and team building, shaping first-class domestic brands with services

In the context of a positive industry, as an industry veteran, Mr. Wang Lichun, founder and chairman of Acchrom-Tech has always remained calm and sober. He said, "The substitution of domestic products is not overnight. To break down the barriers formed by imported brands, it is not only necessary to rely on high-quality and complete product solutions to form 'hard power', but also to rely on professional and systematic sales and service teams to form 'soft power'. After completing product stability and quantity, it is more important to quickly expand the market, let customers see, use, and trust Acchrom-Tech's products."

Guided by this approach, Acchrom-Tech has established a management team, technical team, sales team, and service team in accordance with the standards of international first-class factories. Senior industry experts such as managers, chief engineers, product managers, application managers, and sales managers from multiple international scientific instrument giants have joined Acchrom-Tech in the past year. At the same time, Acchrom-Tech has also cultivated a group of young talents in technology, sales, and application departments according to international enterprise standards. At present, the company has established a complete market sales industry solutions technology and after-sales service system, especially in terms of technical services. Acchrom-Tech has built a technically strong and in-depth application support team to provide customers with highly professional and responsive solutions. At present, the company has developed thousands of application solutions in the fields of chemical medicine, traditional Chinese medicine, food, environment, chemical industry, etc. on its own system.

A towering building rises from the ground. At present, Acchrom-Tech has conducted national standard evaluation and upgrading with multiple national and provincial-level standard making units. This is not only a social responsibility as an excellent domestic chromatography brand enterprise, but also a business foundation that allows a wide range of commercial customers to use Acchrom-Tech's products with more confidence. In the past year, Acchrom-Tech has completed the sales and installation of hundreds of sets of equipment and related consumables in the commercial customer field, with customers covering enterprises and institutions in various fields such as pharmaceuticals, food, environmental protection, petrochemicals, and life sciences. At this point, Acchrom-Tech has already possessed the "hard power+soft power" to compete with international brands, and will welcome the golden age of accelerated domestic substitution of scientific instruments with a comprehensive attitude. In the future, Acchrom-Tech will continuously improve its product and service system, and actively expand its horizontal business in overseas markets, providing customers with a higher quality analysis tool platform.

Various perspectives

Wang Lichun, founder of Acchrom-Tech expressed great gratitude to new and old investment institutions for their recognition and support of Acchrom-Tech Since its establishment 8 years ago, the company has built a complete product ecosystem of chromatography, mass spectrometry, software, consumables, after-sales and application, gathering a large number of elites in the analytical instrument industry. As a national brand of domestic liquid chromatography, Acchrom-Tech shoulders the important responsibility of the rise of domestic analytical instruments. In the future, we will continue to strictly demand ourselves according to international standards, and continue to deliver value to more customers, so that Chinese made analytical instruments can benefit the world!

The Honghui Fund team stated that liquid chromatography is an important field in scientific instruments, and Acchrom-Tech is a leading domestic liquid chromatography company with reliable performance chromatography instruments, consumables, and network software. We look forward to the company's sustained and rapid development, providing better solutions for the life sciences and other industries.

Gao Jieliang, Senior Partner of Dinghui Innovation and Growth Fund, stated that the localization of scientific research instruments has technological and industrial foundations, policy guidance and necessity, and broad market demand support. In the context of industrial upgrading in China, the localization of scientific instruments is the trend. We are optimistic about Acchrom-Tech's leading advantages and development potential in the field of liquid chromatography, which is a billion dollar single product. The company has comprehensively laid out and deeply cultivated the hardware, compliance software, fillers, and application methodology of the chromatograph for many years. The company has gathered first-class talents from the chromatography industry and research institutes at home and abroad. The product has been verified by leading domestic pharmaceutical companies and regulatory agencies, and has also undergone performance testing by Dinghui invested enterprises. Looking ahead to the future, Acchrom-Tech is expected to build a multi category Chinese scientific instrument platform company based on high-performance liquid chromatography, which is a cornerstone product in the field of scientific research instruments. We will also provide long-term support for the company's development.

Li Han, Vice President of Boyuan Capital Investment, expressed gratitude to the new shareholders for their recognition and support of Acchrom-Tech. Since the last round of investment, the company has made significant progress in team building, product research and development, customer introduction, and other aspects in response to the call of the Party and state leaders to "fight a good battle against the localization of scientific instruments and equipment". Boyuan Capital will continue to support Acchrom-Tech and make more contributions to achieving self-reliance and self-improvement in the field of scientific instruments in China.

Chende Capital stated that it continues to be optimistic about Acchrom-Tech's work in the field of liquid chromatography. Under the leadership of Mr. Wang, the company has maintained a consistently excellent level in product development, including software and hardware, consumables, as well as the establishment and improvement of sales and service support systems. I hope that with the continuous support of both new and existing shareholders, Acchrom-Tech can further break the ice of monopoly between domestic and foreign enterprises in the field, and become a first-class enterprise in the field of analytical liquid chromatography.

Wang Keshu, partner of Changhai Capital, expressed his pleasure in continuing to cooperate with Acchrom-Tech and also expressed his gratitude to the new and old shareholders for their continued recognition and support of Acchrom-Tech during the capital winter. The diligent and rational work style of Acchrom-Tech people has enabled Acchrom-Tech to achieve stable mass production of products and establish leading benchmark customers in less than a year. In the future, it will continue to promote product research and development and sales, and become a first-class domestic brand.

About Honghui Fund

To serve Chinese path to modernization, HLC focuses on exploring and realizing the lasting value of science and technology. Based on a deep understanding of core fields such as chemistry, biology, and materials engineering, and based on independent in-depth research and systematic empowerment services, Honghui Fund is committed to creating sustained positive impacts on the transformation of production efficiency and the improvement of people's health and life through long-term value investment in the real economy and technological innovation. So far, Honghui Fund has invested in more than 100 high-quality enterprises, and 25 of them have been listed domestically and internationally. Honghui Fund manages RMB and USD dual currency funds and has established institutions in Shanghai, Beijing, Shenzhen, Hong Kong and other places.

About Dinghui Investment

Dinghui VGC is a fund under Dinghui Investment that focuses on innovation and growth investment. It combines the innovative perspective of venture capital (VC) and the professional rigor of growth investment (Growth), mainly covering four investment areas: healthcare, ToC new consumption, ToB enterprise services, and hard technology innovation. Since its establishment, Dinghui VGC has adhered to the core concept of Dinghui Investment and Strugglers, creating long-term value, and solving social pain points. Through technological innovation or business model innovation, it is its responsibility to help enterprises improve efficiency and reduce costs. It has invested in nearly 90 innovative leading enterprises. Dinghui VGC firmly believes that allocating resources to excellent innovative and growth oriented enterprises will undoubtedly promote the progress of the industry and society.

About Boyuan Capital

Established in 2017, Boyuan Capital is a professional investment institution dedicated to investing in and incubating outstanding medical and health startups in the Chinese market. At present, Boyuan Capital manages two RMB funds and two USD funds, with a total fund management scale exceeding 7 billion yuan. Boyuan Capital is not only an investor, but also a long-term partner of entrepreneurs. Since its establishment, Boyuan Capital has always adhered to the principle of putting entrepreneurs at the center, providing long-term assistance and actively empowering outstanding entrepreneurs in the medical and health industry, building an industry ecosystem, and building a new generation of leading enterprises in China's medical and health industry.

About Chende Capital

Chende Capital is an investment institution focused on innovative medical technology and cutting-edge biotechnology sub sectors. It is managed and operated by a professional team with senior medical industry background, and manages multiple RMB and USD funds under its umbrella.

Chende Capital adheres to the investment philosophy of "focus, excellence, and reputation", based on its profound industrial resources in the medical field and years of in-depth research and cultivation, to gain insight into the latest international technological trends in a timely manner and seize investment opportunities brought about by technological innovation. Chende Capital is committed to discovering top companies with industry leadership potential, and through an interconnected and win-win investment methodology and a precise and pragmatic post investment empowerment system, we work together with entrepreneurs to build an industrial ecosystem, grow together, and create sustainable and excellent returns for investors.

About Changhai Capital

Changhai Capital is a financial advisor specializing in the medical and health field, providing enterprises with in-depth and customized financing strategies and services. The team has rich industry experience in the fields of life sciences, medical devices, IVD, and medical services. They have led and participated in the financing of multiple star enterprises, assisting them in rapid growth and maximizing their value.